Grant: Operating Grant - Priority Announcement: Canadian HIV Vaccine Initiative
Université Laval
$391,824.00
A comparative immunogenicity study of HIV-1 Pr160Gag-Pol virus-like particles bearing gp120, CD40L and/or TLR5 agonist flagellin
FY 2008-09
Summary
Despite current progress, the development of a safe and effective HIV-1 vaccine is still a major concern and an immense challenge. It has been previously demonstrated that virus-like particles (VLPs) are superior to conventional protein immunogens in the activation of immune responses. Unfortunately, HIV-1 has been reported to display a low immunogenicity by itself. To improve immunogenicity of HIV-1-based VLPs, we are proposing to incorporate constituents that can stimulate immune cells into VLPs. We propose that this experimental strategy could enhance and broaden immune responses, which are required for controlling HIV-1 infection.
Department
Program
Operating Grant - Priority Announcement: Canadian HIV Vaccine Initiative
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
186776
Name
Tremblay Michel J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
A comparative immunogenicity study of HIV-1 Pr160Gag-Pol virus-like particles bearing gp120, CD40L and/or TLR5 agonist flagellin
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$391,824
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Canadian HIV Vaccine Initiative
Keyworddelim
Aids; Costimulatory Molecules; Hiv-1 Vaccine; Molecular Biology; Toll-Like Receptors; Virus-Like Particles
Abstract
Despite current progress, the development of a safe and effective HIV-1 vaccine is still a major concern and an immense challenge. It has been previously demonstrated that virus-like particles (VLPs) are superior to conventional protein immunogens in the activation of immune responses. Unfortunately, HIV-1 has been reported to display a low immunogenicity by itself. To improve immunogenicity of HIV-1-based VLPs, we are proposing to incorporate constituents that can stimulate immune cells into VLPs. We propose that this experimental strategy could enhance and broaden immune responses, which are required for controlling HIV-1 infection.
Competitiondate
200903
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tremblay, Michel J
Approvedterm
3 ans 0 mois
Cihrcontribution2
Science Policy 4~ $391,824~ $0~
